A kind of amplification-free nucleic acid detection method and its application

By combining CRISPR technology and digital microfluidic control technology on the microarray chip, nucleic acid detection is directly carried out in the micropore, solving the problems of cumbersome detection process and insufficient sensitivity in the existing technology, and achieving high sensitivity to the new coronavirus. Fast and accurate detection.

CN114540547BActive Publication Date: 2024-11-12SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202210180046.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-02-25
Publication Date
2024-11-12
Estimated Expiration
2042-02-25

AI Technical Summary

Technical Problem

The existing nucleic acid detection methods have problems with cumbersome testing procedures, long time and aerosol contamination caused by nucleic acid amplification in the early diagnosis of novel coronavirus pneumonia, and the sensitivity of the amplification-free technology is not enough to meet clinical needs.

Method used

Micron-level microarray chips are used to realize digital CRISPR detection, and the capture probe reacts with the CRISPR reaction system in the micropores of the microfluidic chip to avoid nucleic acid amplification, improve detection sensitivity and reduce background noise.

Benefits of technology

The detection of nucleic acid molecules as low as 1aM is achieved, which is simple and fast, meets the needs of early clinical diagnosis, and reduces the risk of diffusion dilution and contamination, improving the specificity and accuracy of the detection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114540547B_ABST
    Figure CN114540547B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of nucleic acid detection, and discloses an amplification-free nucleic acid detection method and its application. The nucleic acid detection method of the present invention comprises: capturing the nucleic acid to be detected with a capture probe to form a capture probe-to-be-detected nucleic acid complex; mixing the capture probe-to-be-detected nucleic acid complex with the CRISPR reaction system to form a reaction solution, and passing the reaction solution into the micropores of a microfluidic chip for reaction; and microscopically observing the generated fluorescence to determine the nucleic acid detection result. The present invention combines CRISPR technology with microfluidic technology to develop a nucleic acid detection method, which can achieve single-molecule detection of nucleic acid without nucleic acid amplification, is simple and rapid, does not cause aerosol contamination caused by amplifying nucleic acid, has high sensitivity, and can detect nucleic acid molecules at the attomole level, greatly expanding the scope of use.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of nucleic acid detection, and in particular relates to an amplification-free nucleic acid detection method and application thereof. Background Art

[0002] As a respiratory infectious disease, COVID-19 is mainly caused by COVID-19 infection. Early diagnosis and isolation of COVID-19 patients are currently the key to the prevention and control of this type of disease, among which nucleic acid detection is the gold standard for COVID-19 detection. Current methods for RNA virus nucleic acid detection include reverse transcription PCR (RT-PCR), reverse transcription-loop-mediated isothermal amplification (RT-LAMP), reverse transcription-recombinase polymerase amplification (RT-RPA), etc. However, these technologies have certain disadvantages, such as the need for reverse transcription and nucleic acid amplification, cumbersome detection procedures, long time, and aerosol contamination in nucleic acid amplification. Recombinase polymerase amplification-CRISPR (RPA-CRISPR) is a technology that has attracted widespread attention in recent years. It was first used for gene editing and later for nucleic acid detection. The detection principle is that the target is complementary to CRISPR RNA (crRNA), triggering cis-cleavage and non-specific trans-cleavage of Cas protein, which can cut the probe nucleic acid to produce a fluorescent signal. Many reports have combined CRISPR / Cas technology with nucleic acid amplification to achieve ultra-sensitive detection of nucleic acid molecules. However, these CRISPR-based detections mostly rely on nucleic acid amplification to further amplify the signal of amplified detection and improve detection sensitivity.

[0003] In recent years, researchers have developed some amplification-free nucleic acid detection technologies, but the sensitivity is usually only 1 to 100 femtomoles (fM), which is far from meeting the needs of early clinical diagnosis (1 to 10 attomoles (aM)). Some researchers directly used Cas13a nuclease to detect the new coronavirus and found that its sensitivity reached 100 copies / microliter (approximately 200aM), which is nearly 100 times higher than other amplification-free nucleic acid detection technologies. This is mainly due to the super signal amplification ability of the CRISPR / Cas13a system itself, and it also shows that the CRISPR / Cas system itself has the potential for amplification-free nucleic acid detection. However, the detection system still reacts in a conventional test tube, that is, the entire reaction system is placed in a test tube, and the fluorescent signal in the reaction system is severely diluted, thereby reducing the concentration of the cut fluorescent molecules, and can only be detected when a large amount of fluorescent products are present. Some researchers have used microdroplet digital CRISPR to detect RNA and DNA, but the amount of sample loaded in the droplet method is very small, which may cause missed detection. At the same time, the droplet size is large, about 20 microns, and the fluorescence signal of a single droplet can only be detected after a long reaction time. Therefore, it is of great significance to provide a nucleic acid detection method that can avoid amplification and improve detection sensitivity. Summary of the invention

[0004] The present invention aims to solve at least one of the technical problems existing in the above-mentioned prior art. To this end, the present invention proposes an amplification-free nucleic acid detection method, which uses a micron-level microarray chip to realize digital CRISPR detection, does not require nucleic acid amplification before CRISPR detection, is simple and rapid, has high sensitivity, can detect nucleic acid molecules as low as 1aM, and can meet the needs of early clinical diagnosis.

[0005] The invention also proposes the application of the above detection method.

[0006] According to one aspect of the present invention, a method for amplification-free nucleic acid detection is provided, comprising the following steps:

[0007] S1: Capturing the nucleic acid to be detected with a capture probe to form a capture probe-nucleic acid to be detected complex;

[0008] S2: mixing the capture probe-to-be-detected nucleic acid complex with the CRISPR reaction system to form a reaction solution, and passing the reaction solution into the microwells of the microfluidic chip for reaction;

[0009] The CRISPR reaction system includes Cas protein, CRISPR RNA and reporter probe;

[0010] The volume of the micropores of the microfluidic chip is 30 to 100 fL;

[0011] S3: Perform microscopic observation on the fluorescence generated by the reporter probe described in step S2 to determine the nucleic acid detection result.

[0012] According to a preferred embodiment of the present invention, at least the following beneficial effects are achieved:

[0013] 1. The microwell volume of the microarray chip is very small, only 1% of the volume of the microliquid droplet. The reaction volume of each microwell is at the femtoliter level, which is 1 billion times smaller than the traditional reaction volume. Although there is only one molecule in the microwell, a large amount of fluorescence identified and cut out by the CRISPR reaction system is confined to one microwell, which effectively improves the sensitivity. At the same time, it can exponentially reduce background noise and reduce the diffusion dilution of fluorescence signals by 1 billion times.

[0014] 2. The present invention combines CRISPR technology with digital microfluidics technology to develop a nucleic acid detection method, which can achieve single-molecule detection of nucleic acid without nucleic acid amplification. It is simple and rapid, and will not cause aerosol pollution caused by nucleic acid amplification, greatly expanding the scope of use. In addition, in the prior art, after the nucleic acid to be tested and the CRISPR reaction solution are mixed, the reaction solution is directly placed on a glass slide or a 96-well plate for microscopic observation. This method has extremely poor specificity. However, in the present invention, by combining with a microfluidic chip, it can be ensured that each microwell of the chip contains only one molecule, that is, the specificity is strong, and the single-molecule detection result is more accurate.

[0015] In some embodiments of the present invention, the capture probe in step S1 is combined with magnetic beads, and the diameter of the magnetic beads is 2.6-3.5 μm.

[0016] In some embodiments of the present invention, the capture probe is modified with biotin, and the magnetic beads are modified with streptavidin. Through co-incubation, the biotin and the streptavidin bind to modify the capture probe on the magnetic beads.

[0017] In some embodiments of the invention, the Cas protein includes at least one of Cas13a or Cas13b.

[0018] In some preferred embodiments of the present invention, the Cas protein includes at least one of LwaCas13a (purified from Leptotrichia wadei bacteria), LbuCas13a (purified from Leptotrichia buccalis bacteria), CcaCas13b (purified from Capnocytophaga canimorsus Cc5 bacteria), LbaCas13a (purified from Lachnospiraceaebacterium bacteria), PsmCas13b (purified from Prevotella sp. MA2016 bacteria) or PsmCas13a (purified from Prevotella sp. MA2016 bacteria).

[0019] In some embodiments of the invention, the Cas protein combines with the CRISPR RNA to form a complex.

[0020] In some preferred embodiments of the present invention, the reporter probe is a fluorescent reporter probe, and both ends of the reporter probe are labeled with a fluorescent group and a quencher group.

[0021] The Cas protein has nuclease cleavage activity. When the CRISPR RNA recognizes the capture probe-to-be-tested nucleic acid complex, the CRISPR RNA binds to the to-be-tested nucleic acid through base complementary pairing, which triggers cis-cleavage and non-specific trans-cleavage of the Cas protein. The Cas protein performs non-specific trans-cleavage on the reporter probe, and the fluorescent group on the reporter probe is cleaved into a free state, thereby generating fluorescence.

[0022] In some embodiments of the present invention, the microfluidic chip in step S2 includes 5×10 4 ~5×10 6 Micropores.

[0023] In some embodiments of the present invention, the microfluidic chip in step S2 includes 10 to 500 matrices.

[0024] In some preferred embodiments of the present invention, the microfluidic chip includes 100 matrices.

[0025] In some embodiments of the present invention, each of the matrices comprises 5,000 to 10,000 microwells.

[0026] In some preferred embodiments of the present invention, each of the matrices comprises 10,000 microwells.

[0027] In some embodiments of the present invention, each of the micropores has a diameter of 3.5 to 5 μm and a height of 3.5 to 5 μm.

[0028] In some preferred embodiments of the present invention, each of the micropores has a diameter of 4.4 μm and a height of 3.5 μm.

[0029] In some embodiments of the present invention, the reaction performed in step S2 is a CRISPR reaction, that is, the Cas protein performs non-specific cleavage on the reporter probe, so that the fluorescent group of the reporter probe is cleaved into a free state, and the free fluorescent group generates the fluorescence.

[0030] In some embodiments of the present invention, in the CRISPR reaction, the reaction temperature is 32 to 39° C., and the reaction time is 14 to 16 min.

[0031] In some preferred embodiments of the present invention, the reaction time of the CRISPR reaction is 15 min.

[0032] The reaction time was optimized during the experiment. As the reaction time increased, the fluorescence brightness gradually increased and the number of positive microwells increased. However, when the reaction was carried out for 15 minutes, the fluorescence intensity basically reached saturation. Therefore, 15 minutes was selected as the detection time, which was consistent with the results in the PCR tube. The reaction reached a plateau at around 15 minutes.

[0033] In some embodiments of the present invention, the method of passing the reaction solution into the microfluidic chip in step S2 includes: injecting the reaction solution into the micropores of the microfluidic chip by a microinjection pump, and oil-sealing the microfluidic chip.

[0034] In some embodiments of the present invention, fluorine oil is used for the oil seal.

[0035] In some embodiments of the present invention, the fluoro oil includes at least one of HFE-7500 or FC-40.

[0036] In some embodiments of the present invention, the microscopic observation method in step S3 includes: observing the fluorescence generated by the CRISPR reaction with a microscope.

[0037] In some embodiments of the present invention, the microscope includes at least one of an inverted fluorescence microscope and a laser confocal microscope.

[0038] According to another aspect of the present invention, the application of the nucleic acid detection method in rapid nucleic acid detection for non-diagnostic purposes is proposed.

[0039] In some embodiments of the present invention, the rapid nucleic acid test includes viral nucleic acid detection in the food field or viral nucleic acid detection in the environment.

[0040] At present, due to the widespread spread of the new coronavirus, the new coronavirus may also be present in food and the environment. Therefore, the detection method of the present invention can be used to detect viral nucleic acids before food enters the market, or the outer packaging of goods and the inner wall of the container of the transport vehicle can be used to detect viral nucleic acids in the environment to ensure the safety of food and the environment before putting it on the market. BRIEF DESCRIPTION OF THE DRAWINGS

[0041] The present invention will be further described below with reference to the accompanying drawings and embodiments, wherein:

[0042] Figure 1 is a schematic diagram of a mask used in an embodiment of the present invention;

[0043] Figure 2 The microscopic images of the bottom plate of the microfluidic chip in the embodiment of the present invention are shown in Figure A, where the scale of Figure B is 200 μm, the scale of Figure C is 100 μm, and the scale of Figure A is 50 μm.

[0044] Figure 3 A schematic diagram of a microfluidic chip cover in an embodiment of the present invention;

[0045] Figure 4 This is a flow chart of performing nucleic acid detection in an embodiment of the present invention;

[0046] Figure 5 Fluorescence microscopic imaging images of the influenza virus M gene detected in the embodiments of the present invention and the comparative examples (the first to the last images correspond to Embodiment 8, Embodiment 7, Embodiment 6, Embodiment 5, Embodiment 4, Embodiment 3, Embodiment 1, Embodiment 2, and Comparative Example 1, respectively);

[0047] Figure 6 This is a statistical analysis chart of the results of nucleic acid detection of 20 positive samples and 15 negative samples using the detection method and RT-PCR method of the embodiment of the present invention. DETAILED DESCRIPTION

[0048] Embodiments of the present invention are described in detail below. The described embodiments are exemplary and are only used to explain the present invention, and should not be construed as limiting the present invention.

[0049] In the description of the present invention, unless otherwise clearly defined, terms such as heating and incubation should be understood in a broad sense, and technicians in the relevant technical field can reasonably determine the specific meanings of the above terms in the present invention in combination with the specific content of the technical solution.

[0050] In the description of the present invention, the description with reference to the terms "one embodiment", "some embodiments", etc. means that the specific structure, material or method described in conjunction with the embodiment is included in at least one embodiment of the present invention. In this specification, the schematic representation of the above terms does not necessarily refer to the same embodiment. Moreover, the specific structures, materials or methods described can be combined in any one or more embodiments in a suitable manner.

[0051] Unless otherwise specified, the experimental methods used in the examples are all conventional methods; the materials and reagents used, unless otherwise specified, are all reagents and materials available from commercial sources.

[0052] Example 1

[0053] This example detects the influenza virus M gene at a concentration of 1aM, and the specific process is as follows:

[0054] (1) Preparation of microfluidic chip: a. A layer of silicon nitride was grown on the surface of a 4-inch silicon wafer by vapor deposition, and photoresist SU8-2005 was spin-coated on the silicon nitride using a coating machine. The first stage speed was 500 r / min, the acceleration was 100 (r / min) / s, and the spin coating lasted for 5 to 15 s; the second stage speed was 4000 r / min, the acceleration was 500 (r / min) / s, and the spin coating lasted for 20 to 50 s. The silicon wafer after spin coating with photoresist was placed on a 95°C hot plate and baked for 3 min;

[0055] b. Use SUSS MA6 lithography machine to load the mask (such as Figure 1 As shown, the mask is designed to include 100 matrices, each matrix includes 10,000 small circles, each small circle has a diameter of 4.4 μm, and the center spacing of the small circles is 10 μm) and a silicon wafer whose temperature is reduced to room temperature after baking, UV exposure for 10 to 20 seconds, and the exposed silicon wafer is placed on a 95°C hot plate for baking for 2 to 5 minutes; the silicon wafer whose temperature is reduced to room temperature after baking is immersed in SU-8 developer for development for 10 to 40 seconds, then rinsed with isopropyl alcohol and blown dry with an air gun, and the blown-dried silicon wafer is placed on a 150°C hot plate for baking for 20 to 40 minutes;

[0056] c. Using the evaporated platinum layer as a catalyst, a microporous structure with a depth of 3.5 μm is processed at the position of each small circle on the silicon wafer through an anisotropic metal-assisted chemical etching method; the catalyst is removed, and etching is performed with an etching solution. After 8 to 12 minutes, the silicon wafer is taken out and cleaned;

[0057] d. Coat a polydimethylsiloxane (PDMS) layer on the surface of the silicon wafer, remove bubbles in a vacuum drying oven, and heat and cure. After curing, peel the PDMS layer from the silicon wafer to obtain the microfluidic chip base plate, and put it into a plasma cleaner together with the upper cover prepared by the same operation for plasma treatment. Then, fit the upper cover and the base plate together and bake for 5 minutes to make the microfluidic chip.

[0058] Microscopic imaging of the microfluidic chip base plate Figure 2 As shown, the chip base plate includes 100 matrices, each matrix includes 10,000 micropores, each micropore has a diameter of 4.4 μm, a height of 3.5 μm, and a center distance of 10 μm, wherein A is a portion of the chip base plate, including 2 matrices, B is an enlarged view of one matrix in A, including 10,000 micropores, and C is a partial enlarged view of B, and each micropore has a diameter of 4.4 μm.

[0059] The schematic diagram of the microfluidic chip cover is as follows Figure 3As shown, there are two ports on the upper cover for liquid to enter and exit, one of which is the liquid inlet and the other is the liquid outlet; the middle part of the upper cover is a 100μm high space for liquid to flow through, that is, the liquid enters the microfluidic chip from the inlet of the upper cover, flows through the middle part for reaction, and then discharges the waste liquid from the outlet of the upper cover.

[0060] (2) Detect the influenza virus M gene. The specific process is as follows: Figure 4 a. First, the streptavidin-modified magnetic beads MB and the biotin-modified capture probe (the capture probe is shown in SEQ ID NO: 1, and the specific sequence is atcctaaaattcccttagtcag) are co-incubated for 30 minutes to modify the capture probe on the magnetic beads MB, rinsed with phosphate buffer (PBS) 3 times, resuspended with 20 μL PBS, added to 500 μL of lysed influenza virus sample (wherein the concentration of influenza virus M gene is 1aM), and the influenza virus M gene is captured by the capture probe for 30 minutes, and the magnetic beads MB are captured by magnet adsorption, washed with PBS 3 times, and resuspended with 20 μL PBS, and the suspension includes the magnetic beads MB-capture probe-influenza virus M gene complex;

[0061] b. Prepare CRISPR reaction system (reaction buffer (50mM NaCl, 10mM Tris-HCl, 10mM MgCl2, 100μg / mL BSA, pH=7.9), LwaCas13a protein (purified from Leptotrichia wadei bacteria), CRISPR RNA (as shown in SEQ ID NO: 2, the specific sequence is: gaccaccccaaaaaugaaggggacuaaaaccuugucuuuagccauuccaugag) and fluorescent reporter probe, the two ends of the fluorescent reporter probe are labeled with a fluorescent group F and a quenching group Q, the sequence of the fluorescent reporter probe is FAM-tttatt-BHQ1, wherein FAM is a fluorescent group F, emitting green fluorescence, and BHQ1 is a quenching group Q;

[0062] c. Add the magnetic bead MB-capture probe-influenza virus M gene complex prepared in a to the CRISPR reaction system in b, mix well to form a reaction solution, inject 20 μL of the reaction solution into the micropores of the microfluidic chip through a microinjection pump at a flow rate of 10 μL / min, and then inject fluoro oil FC-40 into the micropores of the microfluidic chip for oil sealing, so that the reaction in each micropore is divided into a separate reaction, and heat the microfluidic chip from the bottom to 32-39°C to perform a CRISPR reaction;

[0063] Because the number of targets is far less than 1 million, theoretically there is only one nucleic acid to be tested in each microwell. The initial experiment (without magnetic beads) found that many microwells produced fluorescence, but the number was far less than the number of nucleic acids to be tested. This is because the total volume of 1 million microwells is only 50nL (i.e. Figure 4 50fL×10 6 ), and during the experiment, 20μL of reaction solution was introduced, and most of the nucleic acid to be tested was washed away by FC-40. Although monodisperse detection was achieved, it would lead to false negative results for samples with low nucleic acid content to be tested, resulting in missed detection. Therefore, magnetic beads were further introduced into the system. Due to their high density, magnetic beads would sink into the microwells, and excess magnetic beads would be pushed into the microwells by FC-40. After many attempts, it was found that when magnetic beads were added twice the number of microwells, more than 50% of the microwells basically contained one magnetic bead in each microwell, so 2 million magnetic beads were added to each reaction system.

[0064] d. After 15 minutes of reaction, the microfluidic chip was placed under an inverted fluorescence microscope for observation, photographing, and counting and analysis using ImageJ software;

[0065] When the CRISPR reaction is carried out in the microwell, if there is an influenza virus M gene to be detected in the microwell, the CRISPR RNA will bind to the influenza virus M gene through base complementary pairing, which will trigger the cis-cleavage and non-specific trans-cleavage of the Cas13a protein. The Cas13a protein performs non-specific trans-cleavage on the fluorescent reporter probe, and the fluorescent group FAM on the fluorescent reporter probe is cleaved into a free state, thereby generating green fluorescence. A large number of fluorescent groups gather in the microwell, and green fluorescence can be observed under a microscope;

[0066] If there is no influenza virus M gene to be detected in the microwell, but only the capture probe connected to the magnetic bead MB, the CRISPR RNA will not recognize the target and will not trigger the cutting behavior of the Cas13a protein. The fluorescent group of the fluorescent reporter probe will not be cut, and no free fluorescent group will be generated in the corresponding microwell, so no fluorescence will be observed under a microscope.

[0067] Example 2

[0068] In this example, the influenza virus M gene at a concentration of 0.1aM was detected, and the specific process was the same as that of Example 1.

[0069] Example 3

[0070] In this example, the influenza virus M gene at a concentration of 10aM was detected, and the specific process was the same as that of Example 1.

[0071] Example 4

[0072] In this example, the influenza virus M gene at a concentration of 100 aM was detected, and the specific process was the same as that of Example 1.

[0073] Example 5

[0074] In this example, the influenza virus M gene at a concentration of 1 fM was detected, and the specific process was the same as that of Example 1.

[0075] Example 6

[0076] In this example, the influenza virus M gene at a concentration of 10 fM was detected, and the specific process was the same as that of Example 1.

[0077] Example 7

[0078] In this example, the influenza virus M gene at a concentration of 100 fM was detected, and the specific process was the same as that of Example 1.

[0079] Example 8

[0080] In this example, the influenza virus M gene at a concentration of 1 pM was detected, and the specific process was the same as that of Example 1.

[0081] Comparative Example 1

[0082] This comparative example also performed nucleic acid testing. The difference from Example 1 is that no influenza virus sample was added in this comparative example, that is, the concentration of the influenza virus M gene was 0, and the rest of the process was the same as that of Example 1.

[0083] Test example

[0084] This test example tested the detection results of influenza virus M gene at different concentrations in Examples 1 to 8 and Comparative Example 1 by microscopic observation and analyzed the detection sensitivity.

[0085] The detection results of influenza virus M gene in Examples 1 to 8 and Comparative Example 1 are as follows: Figure 5 shown. Figure 5In the embodiment 1 (the concentration of influenza virus M gene was 1aM), no green fluorescence was observed in the micropores of comparative example 1 (no influenza virus sample was added) and embodiment 2 (the concentration of influenza virus M gene was 0.1aM); green fluorescence was observed in the micropores of embodiment 1 (the concentration of influenza virus M gene was 1aM), and the number of micropores showing green fluorescence was small, and one micropore showing green fluorescence was observed in the field of view; three micropores showing green fluorescence were observed in the field of view of embodiment 3 (the concentration of influenza virus M gene was 10aM); the number of micropores showing green fluorescence in the field of view of embodiment 4 (the concentration of influenza virus M gene was 100aM) increased; in embodiment 5 (the concentration of influenza virus M gene was 1fM), embodiment 6 (the concentration of influenza virus M gene was 10fM), embodiment 7 (the concentration of influenza virus M gene was 100fM) and embodiment 8 (the concentration of influenza virus M gene was 1pM), as the concentration of influenza virus M gene increased, the number of micropores showing green fluorescence gradually increased.

[0086] From the above results, it can be seen that the nucleic acid detection method of the present invention can detect nucleic acid molecules as low as 1aM to be detected, which is more than 100 times more sensitive than the conventional amplification-free method.

[0087] In addition, the inventors used real influenza virus samples collected from hospitals, including 20 positive samples and 15 negative samples, and used the nucleic acid detection method of the present invention for detection, using the RT-PCR method as a control method. The statistical analysis results of the detection are as follows: Figure 6 As shown, the detection results of 20 positive samples and 15 negative samples using the detection method of the present invention and the RT-PCR method are consistent, indicating that the nucleic acid detection method of the present invention can be used for the detection of actual samples.

[0088] The above is a detailed description of the embodiments of the present invention, but the present invention is not limited to the above embodiments. Various changes can be made within the knowledge of ordinary technicians in the relevant technical field without departing from the purpose of the present invention. In addition, the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict. SEQUENCE LISTING <110> Southern University of Science and Technology <120> A kind of amplification-free nucleic acid detection method and its application <130> 1 <160> 2 <170> PatentIn version 3.5 <210> 1 <211> twenty two <212> DNA <213> Artificial sequence <400> 1 atcctaaaat tcccttagtc ag 22 <210> 2 <211> 53 <212> RNA <213> Artificial sequence <400> 2 gaccacccca aaaaugaagg ggacuaaaac cuugucuuua gccauuccau gag 53

Claims

1. A method for detecting nucleic acid of influenza virus M gene without amplification, It is characterized in that The following steps are involved: S1: Capturing the nucleic acid to be detected with a capture probe to form a capture probe-nucleic acid to be detected complex; the capture probe sequence is shown in SEQ ID NO: 1; S2: mixing the capture probe-to-be-detected nucleic acid complex with the CRISPR reaction system to form a reaction solution, and passing the reaction solution into the microwells of the microfluidic chip for reaction; The CRISPR reaction system includes Cas protein, CRISPR RNA and reporter probe; the CRISPR RNA sequence is shown in SEQ ID NO: 2; The volume of the micropores of the microfluidic chip is 30 to 100 fL; S3: performing microscopic observation on the fluorescence generated by the reporter probe in step S2 to determine the nucleic acid detection result; The capture probe described in step S1 is combined with magnetic beads, and the diameter of the magnetic beads is 2.6 to 3.5 μm; The capture probe is modified with biotin, and the magnetic beads are modified with streptavidin. Through co-incubation, the biotin and the streptavidin bind to modify the capture probe on the magnetic beads; the detection method is not intended for the diagnosis or treatment of diseases.

2. The detection method according to claim 1, It is characterized in that The Cas protein includes at least one of Cas13a or Cas13b.

3. The detection method according to claim 1, It is characterized in that Both ends of the reporter probe are labeled with a fluorescent group and a quenching group.

4. The detection method according to claim 1, It is characterized in that The microfluidic chip in step S2 includes 5×10 4 ~5×10 6 Micropores.

5. The detection method according to claim 1, It is characterized in that The reaction performed in step S2 is a CRISPR reaction: the Cas protein performs non-specific cleavage on the reporter probe, so that the fluorescent group of the reporter probe is cleaved into a free state, and the free fluorescent group generates fluorescence.

6. The detection method according to claim 5, It is characterized in that In the CRISPR reaction, the reaction temperature is 32 to 39° C. and the reaction time is 14 to 16 minutes.

7. The detection method according to claim 1, It is characterized in that The microscopic observation method in step S3 includes: observing the fluorescence generated by the reporter probe using a microscope.

8. Use of the detection method according to any one of claims 1 to 7 in rapid nucleic acid detection for non-diagnostic purposes, It is characterized in that The nucleic acid rapid test includes the detection of viral nucleic acid in the environment; the viral nucleic acid is the nucleic acid of the influenza virus M gene.

Citation Information

Cited By

  • Integrated device and method for nucleic acid extraction and multiple nucleic acid analysis

    CN121271698A